Managing Spironolactone in Patients with Hypomagnesemia and Hyponatremia

Initial Assessment and Spironolactone Discontinuation

The European Heart Journal recommends stopping spironolactone immediately if serum sodium is <125 mmol/L (severe hyponatremia) 1, 2, 3, 4
In patients with hypovolaemic hyponatremia, the European Heart Journal suggests expansion of plasma volume with normal saline and cessation of all diuretics including spironolactone 3, 4
For hypervolaemic hyponatremia, management focuses on sodium restriction rather than fluid restriction unless sodium <125 mmol/L with clinical hypervolemia 3, 4

The European Heart Journal recommends discontinuing all diuretics including spironolactone for severe hyponatremia (Na <125 mmol/L) 2, 3, 4
If hypovolaemic, expand plasma volume with normal saline 3, 4
If hypervolaemic with clinical fluid overload, implement fluid restriction to 1-1.5 L/day 2, 3, 4
Avoid increasing serum sodium by >12 mmol/L per 24 hours to prevent osmotic demyelination syndrome 1

The Journal of the American College of Cardiology recommends reinitiating spironolactone at 12.5-25 mg daily (or alternate days in high-risk patients) once electrolytes are corrected (Na ≥125 mmol/L, Mg normalized) 7
Monitor potassium, sodium, magnesium, and creatinine within 3 days, then at 1 week after initiation, and continue monitoring every 5-7 days until values are stable 5, 6, 7

Stop or reduce spironolactone if serum sodium drops to <125 mmol/L 2, 3, 4
Stop or reduce spironolactone if hyperkalemia develops (K >5.5 mEq/L) 7
Stop or reduce spironolactone if serum creatinine rises substantially 5
Stop or reduce spironolactone if hypomagnesemia recurs despite supplementation 6

The European Heart Journal recommends avoiding NSAIDs and COX-2 inhibitors, which worsen renal function and increase hyperkalemia risk 5, 7
Exercise extreme caution with ACE inhibitors/ARBs, as the combination increases hyperkalemia risk dramatically (up to 24% incidence vs 2% in trials) 7
Avoid triple therapy (ACEI + ARB + spironolactone) 7

In cirrhosis with ascites, spironolactone is the mainstay of therapy, but requires more cautious use with baseline hyponatremia 8, 1, 9
Consider amiloride (10-40 mg/day) as alternative if spironolactone cannot be tolerated 8, 1
Ensure dietary sodium restriction to 5-6.5 g/day (87-113 mmol) 2